<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03198325</url>
  </required_header>
  <id_info>
    <org_study_id>APACHE Study</org_study_id>
    <nct_id>NCT03198325</nct_id>
  </id_info>
  <brief_title>Monitored Antiretroviral Pause in Chronic HIV-Infected Subjects With Long-Lasting Suppressed Viremia</brief_title>
  <acronym>APACHE</acronym>
  <official_title>Monitored Antiretroviral Pause in Chronic HIV-Infected Subjects With Long-Lasting Suppressed Viremia (APACHE Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ospedale San Raffaele</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, open-label, single arm, non-randomized, proof-of-concept study. Eligible
      patients will sign a written informed consent and will be followed-up at screening, baseline
      (ART interruption) and at 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 32, 40, 48 weeks thereafter or at
      ART resumption.

      The study visits will include: general clinical assessment, routine laboratory tests
      including: creatinine, phosphorus, calcium, alkaline phosphatase, AST, ALT, fasting glucose,
      total cholesterol, HDL- and LDL-cholesterol, triglycerides, CD4+ cell count and CD4+/CD8+
      ratio.

      Additional 30 mL of peripheral blood will be withdrawn at study visits for further
      virological, and immunological investigations and for bio-banking purposes.

      During follow-up, the occurrence of two consecutive HIV-1 RNA values &gt;50 copies/mL or the
      occurrence of stage B or C AIDS-defining events or any serious non-AIDS clinical event at
      least potentially related to treatment interruption will be criteria for ART resumption.

      All patients with HIV-RNA&lt;50 copies/mL at week 48 (end of the study) will resume their
      baseline ART regimen.

      The main demographic, clinical and therapy information will be accurately recorded at the
      study visits in an electronic Case Report Form.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this proof-of-concept study on adult (&gt;18 and &lt;65 years old), chronically HIV-1
      infected individuals with undetectable viremia for ≥10 years, undetectable HIV-DNA, CD4+≥500
      cells/µL and no evidence of detectable residual viremia for ≥5 years is to evaluate the
      frequency of spontaneous control of virus replication after ART pausing for up to 12 months
      and to identify the virological and immunological markers associated with spontaneous control
      of viral replication.

      Prospective, open-label, single arm, non-randomized, proof-of-concept study.

      Eligible patients will sign a written informed consent and will be followed-up at screening,
      baseline (ART interruption) and at 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 32, 40, 48 weeks
      thereafter or at ART resumption.

      The clinical assessment (study visit) will include: the evaluation of CDC stage, height,
      weight, systolic and diastolic blood pressure and smoking status, routine laboratory tests
      [including creatinine, phosphorus, calcium, alkaline phosphatase, AST, ALT, fasting glucose,
      total cholesterol, HDL- and LDL-cholesterol, triglycerides, CD4+ cell count and CD4+/CD8+
      ratio, urine analysis].

      Additional 30 mL of peripheral blood will be withdrawn at study visits and stored in a
      biobank for further investigations.

      During follow-up, the occurrence of two consecutive HIV-1 RNA values &gt;50 copies/mL or the
      occurrence of stage B or C AIDS-defining events will be criteria for ART resumption or any
      serious non-AIDS clinical event at least potentially related to treatment interruption.

      All patients with HIV-RNA&lt;50 copies/mL at week 48 (end of the study) will resume their
      baseline ART regimen.

      The main demographic, clinical and therapy information will be accurately recorded at the
      study visits in an electronic Case Report Form (eCRF).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 27, 2016</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients who will not resume antiretroviral regimen</measure>
    <time_frame>12 month</time_frame>
    <description>Cumulative proportion of patients who will not resume ART 12 months after IMAP (Monitored Antiretroviral Pause) due to the occurrence of two consecutive HIV-1 RNA values &gt;50 copies/mL or the occurrence of stage B or C AIDS-defining events or any serious non-AIDS clinical event at least potentially related to treatment interruption.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in plasma viremia</measure>
    <time_frame>1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 32, 40, 48 weeks thereafter or at ART resumption.</time_frame>
    <description>Change in plasma viremia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma HIV-DNA</measure>
    <time_frame>1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 32, 40, 48 weeks thereafter or at ART resumption.</time_frame>
    <description>Change in plasma HIV-DNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4+</measure>
    <time_frame>1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 32, 40, 48 weeks thereafter or at ART resumption.</time_frame>
    <description>Change in CD4+</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4+/CD8+ ratio</measure>
    <time_frame>1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 32, 40, 48 weeks thereafter or at ART resumption.</time_frame>
    <description>Change in CD4+/CD8+ ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in virological biomarkers</measure>
    <time_frame>1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 32, 40, 48 weeks thereafter or at ART resumption.</time_frame>
    <description>Change in virological biomarkers prior to ART interruption and/or at ART resumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in immunological biomarkers</measure>
    <time_frame>1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 32, 40, 48 weeks thereafter or at ART resumption.</time_frame>
    <description>Change in immunological biomarkers prior to ART interruption and/or at ART resumption</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>HIV Seropositivity</condition>
  <arm_group>
    <arm_group_label>Interruption of antiretroviral therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients willing to stop antiretroviral therapy will stop ART.The occurrence of two consecutive HIV-1 RNA values &gt;50 copies/mL or the occurrence of stage B or C AIDS-defining events will be criteria for ART resumption or any serious non-AIDS clinical event at least potentially related to treatment interruption.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stop of ART</intervention_name>
    <description>Patients willing to stop antiretroviral therapy will stop ART.The occurrence of two consecutive HIV-1 RNA values &gt;50 copies/mL or the occurrence of stage B or C AIDS-defining events will be criteria for ART resumption or any serious non-AIDS clinical event at least potentially related to treatment interruption.</description>
    <arm_group_label>Interruption of antiretroviral therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The study will include HIV-1 infected:

          -  men and non-pregnant women,

          -  ≥18 and &lt;65 years-old,

          -  asking to stop therapy,

          -  with HIV-1 RNA&lt;50 copies/mL for ≥10 years,

          -  current CD4+≥500 cells/µL,

          -  HIV-DNA&lt;100 copies/106PBMCs,

          -  no evidence of detectable residual viremia for ≥5 years .

        Exclusion Criteria:

        The study will exclude HIV-1 infected subjects:

          -  significant risk of HIV transmission during IMAP (including evidence of not adopting
             effective contraception methods and women who wish to be pregnant) in the opinion of
             the investigator,

          -  pregnancy and breastfeeding,

          -  a documented pre-ART HIV-1 RNA&lt;200 copies/mL,

          -  reactive Hepatitis B virus (HBV) surface antigen,

          -  positive HCV-RNA at the time of screening,

          -  current AIDS defining event as defined in category C of the 'Centers for disease
             control and prevention (CDC)' clinical classification,

          -  previous diagnosis of diabetes,

          -  a previous diagnosis of cancer or major adverse cardiac events (MACE) and currently
             receiving chemotherapy or immuno-modulating agents at the time of screening,

          -  history of HIV-related thrombocytopenia,

          -  active renal disease defined as a glomerular filtration rate (calculated by MDRD
             equation) below 50 mL/min or the presence of HIV associated nephropathy in the past
             medical history,

          -  any condition, including psychiatric or psychological disorders that might interfere
             with adherence to study requirements or safety of the participant,

          -  prior use of any HIV vaccine and/or non-established experimental therapy,

          -  active drug or alcohol use or dependence that, in the opinion of the site
             investigator, would interfere with adherence to study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antonella Castagna, Professor</last_name>
    <phone>00390226437934</phone>
    <email>castagna.antonella1@hsr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisabetta Carini, MD</last_name>
    <phone>00390226437934</phone>
    <email>carini.elisabetta@hsr.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale San Raffaele Scientific Institute</name>
      <address>
        <city>Milan</city>
        <zip>20127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabetta Carini</last_name>
      <phone>0039022643</phone>
      <phone_ext>7934</phone_ext>
      <email>carini.elisabetta@hsr.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Pau AK, George JM. Antiretroviral therapy: current drugs. Infect Dis Clin North Am. 2014 Sep;28(3):371-402. doi: 10.1016/j.idc.2014.06.001. Review.</citation>
    <PMID>25151562</PMID>
  </reference>
  <reference>
    <citation>Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fätkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006 Nov 30;355(22):2283-96.</citation>
    <PMID>17135583</PMID>
  </reference>
  <reference>
    <citation>Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, Girard PM, Grund B, Law M, Losso MH, Palfreeman A, Wood R. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008 Apr 15;197(8):1133-44. doi: 10.1086/586713.</citation>
    <PMID>18476292</PMID>
  </reference>
  <reference>
    <citation>Skiest DJ, Krambrink A, Su Z, Robertson KR, Margolis DM; A5170 Study Team. Improved measures of quality of life, lipid profile, and lipoatrophy after treatment interruption in HIV-infected patients with immune preservation: results of ACTG 5170. J Acquir Immune Defic Syndr. 2008 Dec 1;49(4):377-83. doi: 10.1097/QAI.0b013e31818cde21.</citation>
    <PMID>18931631</PMID>
  </reference>
  <reference>
    <citation>Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis. 2008 Apr 15;197(8):1145-55. doi: 10.1086/529523.</citation>
    <PMID>18476293</PMID>
  </reference>
  <reference>
    <citation>Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, Potard V, Versmisse P, Melard A, Prazuck T, Descours B, Guergnon J, Viard JP, Boufassa F, Lambotte O, Goujard C, Meyer L, Costagliola D, Venet A, Pancino G, Autran B, Rouzioux C; ANRS VISCONTI Study Group. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 2013 Mar;9(3):e1003211. doi: 10.1371/journal.ppat.1003211. Epub 2013 Mar 14.</citation>
    <PMID>23516360</PMID>
  </reference>
  <reference>
    <citation>Williams JP, Hurst J, Stöhr W, Robinson N, Brown H, Fisher M, Kinloch S, Cooper D, Schechter M, Tambussi G, Fidler S, Carrington M, Babiker A, Weber J, Koelsch KK, Kelleher AD, Phillips RE, Frater J; SPARTACTrial Investigators. HIV-1 DNA predicts disease progression and post-treatment virological control. Elife. 2014 Sep 12;3:e03821. doi: 10.7554/eLife.03821.</citation>
    <PMID>25217531</PMID>
  </reference>
  <reference>
    <citation>Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, Lai J, Blankson JN, Siliciano JD, Siliciano RF. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell. 2013 Oct 24;155(3):540-51. doi: 10.1016/j.cell.2013.09.020. Epub 2013 Oct 24.</citation>
    <PMID>24243014</PMID>
  </reference>
  <reference>
    <citation>Hurst J, Hoffmann M, Pace M, Williams JP, Thornhill J, Hamlyn E, Meyerowitz J, Willberg C, Koelsch KK, Robinson N, Brown H, Fisher M, Kinloch S, Cooper DA, Schechter M, Tambussi G, Fidler S, Babiker A, Weber J, Kelleher AD, Phillips RE, Frater J. Immunological biomarkers predict HIV-1 viral rebound after treatment interruption. Nat Commun. 2015 Oct 9;6:8495. doi: 10.1038/ncomms9495.</citation>
    <PMID>26449164</PMID>
  </reference>
  <reference>
    <citation>Lee SA, Bacchetti P, Chomont N, Fromentin R, Lewin SR, O'Doherty U, Palmer S, Richman DD, Siliciano JD, Yukl SA, Deeks SG, Burbelo PD. Anti-HIV Antibody Responses and the HIV Reservoir Size during Antiretroviral Therapy. PLoS One. 2016 Aug 2;11(8):e0160192. doi: 10.1371/journal.pone.0160192. eCollection 2016.</citation>
    <PMID>27483366</PMID>
  </reference>
  <reference>
    <citation>Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, Siliciano RF. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003 Jun;9(6):727-8. Epub 2003 May 18.</citation>
    <PMID>12754504</PMID>
  </reference>
  <reference>
    <citation>Burbelo PD, Lebovitz EE, Notkins AL. Luciferase immunoprecipitation systems for measuring antibodies in autoimmune and infectious diseases. Transl Res. 2015 Feb;165(2):325-35. doi: 10.1016/j.trsl.2014.08.006. Epub 2014 Sep 1. Review.</citation>
    <PMID>25241936</PMID>
  </reference>
  <reference>
    <citation>Assoumou L, Weiss L, Piketty C, Burgard M, Melard A, Girard PM, Rouzioux C, Costagliola D; ANRS 116 SALTO study group. A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control. AIDS. 2015 Sep 24;29(15):2003-7. doi: 10.1097/QAD.0000000000000734.</citation>
    <PMID>26355572</PMID>
  </reference>
  <reference>
    <citation>Calin R, Hamimi C, Lambert-Niclot S, Carcelain G, Bellet J, Assoumou L, Tubiana R, Calvez V, Dudoit Y, Costagliola D, Autran B, Katlama C; ULTRASTOP Study Group. Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir. AIDS. 2016 Mar 13;30(5):761-9. doi: 10.1097/QAD.0000000000000987.</citation>
    <PMID>26730568</PMID>
  </reference>
  <reference>
    <citation>Cuzin L, Pugliese P, Sauné K, Allavena C, Ghosn J, Cottalorda J, Rodallec A, Chaix ML, Fafi-Kremer S, Soulié C, Ouka M, Charpentier C, Bocket L, Mirand A, Guiguet M; Dat’AIDS study group. Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy. AIDS. 2015 Aug 24;29(13):1665-71. doi: 10.1097/QAD.0000000000000723.</citation>
    <PMID>26372277</PMID>
  </reference>
  <reference>
    <citation>Zheng L, Bosch RJ, Chan ES, Read S, Kearney M, Margolis DM, Mellors JW, Eron JJ, Gandhi RT; DS Clinical Trials Group (ACTG) A5244 Team. Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy. Antivir Ther. 2013;18(1):39-43. doi: 10.3851/IMP2323. Epub 2012 Aug 22.</citation>
    <PMID>22914318</PMID>
  </reference>
  <reference>
    <citation>Maggiolo F, Callegaro A, Cologni G, Bernardini C, Velenti D, Gregis G, Quinzan G, Soavi L, Iannotti N, Malfatto E, Leone S. Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure. J Acquir Immune Defic Syndr. 2012 Aug 15;60(5):473-82. doi: 10.1097/QAI.0b013e3182567a57.</citation>
    <PMID>22481602</PMID>
  </reference>
  <reference>
    <citation>Gianotti N, Canducci F, Galli L, Cossarini F, Salpietro S, Poli A, Nozza S, Spagnuolo V, Clementi M, Sampaolo M, Ceresola ER, Racca S, Lazzarin A, Castagna A. HIV DNA loads, plasma residual viraemia and risk of virological rebound in heavily treated, virologically suppressed HIV-infected patients. Clin Microbiol Infect. 2015 Jan;21(1):103.e7-103.e10. doi: 10.1016/j.cmi.2014.08.004. Epub 2014 Oct 13.</citation>
    <PMID>25636935</PMID>
  </reference>
  <reference>
    <citation>Li JZ, Etemad B, Ahmed H, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR, Lederman MM, Para M, Gandhi RT. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS. 2016 Jan 28;30(3):343-53. doi: 10.1097/QAD.0000000000000953.</citation>
    <PMID>26588174</PMID>
  </reference>
  <reference>
    <citation>Tedaldi E, Peters L, Neuhaus J, Puoti M, Rockstroh J, Klein MB, Dore GJ, Mocroft A, Soriano V, Clotet B, Lundgren JD; SMART Study Group and International Network for Strategic Initiatives in Global HIV Trials (INSIGHT). Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis. 2008 Dec 1;47(11):1468-75. doi: 10.1086/593102.</citation>
    <PMID>18959492</PMID>
  </reference>
  <reference>
    <citation>Monroe AK, Chander G, Moore RD. Control of medical comorbidities in individuals with HIV. J Acquir Immune Defic Syndr. 2011 Dec 15;58(5):458-62. doi: 10.1097/QAI.0b013e31823801c4.</citation>
    <PMID>22083037</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2017</study_first_submitted>
  <study_first_submitted_qc>June 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2017</study_first_posted>
  <last_update_submitted>June 22, 2017</last_update_submitted>
  <last_update_submitted_qc>June 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale San Raffaele</investigator_affiliation>
    <investigator_full_name>Castagna Antonella</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Viremia</mesh_term>
    <mesh_term>HIV Seropositivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Congress and scientific pubblications</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

